176 related articles for article (PubMed ID: 36465923)
1. Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach.
Vivekanandan S; Vetrivel U; Hanna LE
Front Med (Lausanne); 2022; 9():1036874. PubMed ID: 36465923
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
3. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
4. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
5. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
[TBL] [Abstract][Full Text] [Related]
6. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
[TBL] [Abstract][Full Text] [Related]
7. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
8. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
9. CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.
Kumar S; Kumar R; Khan L; Makhdoomi MA; Thiruvengadam R; Mohata M; Agarwal M; Lodha R; Kabra SK; Sinha S; Luthra K
Front Immunol; 2017; 8():1568. PubMed ID: 29187855
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
12. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.
Planque S; Salas M; Mitsuda Y; Sienczyk M; Escobar MA; Mooney JP; Morris MK; Nishiyama Y; Ghosh D; Kumar A; Gao F; Hanson CV; Paul S
AIDS; 2010 Mar; 24(6):875-84. PubMed ID: 20186035
[TBL] [Abstract][Full Text] [Related]
14. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
16. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
[TBL] [Abstract][Full Text] [Related]
17. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.
Cheng HD; Grimm SK; Gilman MS; Gwom LC; Sok D; Sundling C; Donofrio G; Karlsson Hedestam GB; Bonsignori M; Haynes BF; Lahey TP; Maro I; von Reyn CF; Gorny MK; Zolla-Pazner S; Walker BD; Alter G; Burton DR; Robb ML; Krebs SJ; Seaman MS; Bailey-Kellogg C; Ackerman ME
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515029
[TBL] [Abstract][Full Text] [Related]
18. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
20. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
